NEWS
Collaboration to advance proteomics solutions
Antibody and protein development firm Leinco Technologies and CellCarta, a provider of precision medicine laboratory services, have announced a strategic collaboration aimed at advancing proteomics solutions that will benefit the development of immuno- oncology and other targeted therapeutic modalities.
This partnership combines Leinco’s
extensive antibody portfolio - specifically, high-quality antibodies validated for critical tissue analysis applications like immunohistochemistry (IHC) and a growing range of spatial biology platforms – with CellCarta’s catalogue of CPTAC antibodies developed for its Immuno-MRM assays. This integration provides researchers and clinicians with comprehensive tools for biomarker discovery and clinical research. CellCarta’s Immuno-MRM assays
offer highly multiplexed and quantitative protein measurements, enabling precise quantification of specific targets in clinical samples. These assays provide valuable insights into protein expression and functionality and utilise antibodies that were validated to meet CPTAC consortium standards. The antibody library was designed to support research at all levels, from exploratory to clinical trials. By integrating Leinco’s high-
quality, validated antibodies with CellCarta’s Immuno-MRM resources, the collaboration aims to enhance the sensitivity and specificity of proteomic analyses, facilitating the development of targeted therapies and personalised medicine approaches. “The combination of our rigorously
validated antibodies – especially those proven for complex spatial analysis and IHC - with CellCarta’s robust Immuno- MRM resources creates a truly powerful and scalable solution for our customers,” said Patrick Leinert Jr, President of Commercial Operations at Leinco Technologies. “This strategic pairing is designed to provide confidence in data quality that is absolutely essential for accelerating drug development and biomarker discovery in all therapeutic areas.”
UK and US step up medtech cooperation
The Medicines and Healthcare products Regulatory Agency (MHRA) is stepping up its collaboration with the US Food and Drug Administration (FDA) to support faster access to safe and innovative medical technologies in the future for patients in both countries. The announcement of the new US- UK pharmaceutical partnership further strengthens this collaboration while also removing tariffs on UK medicines exports and encourages companies to bring cuting edge treatments to the UK earlier. The MHRA and FDA will work closely on
options to improve and align regulations for medical devices. This includes exploring future mutual recognition mechanisms (ways to recognise parts of the individual approval processes), reducing duplication for manufacturers and streamlining approval processes to help patients access new medical technologies sooner. Both regulators’ work will remain independent and ensure strict safety standards are maintained.
Lawrence Tallon, MHRA Chief Executive, said: “This marks an exciting moment for UK innovation. By strengthening our working relationship with the FDA, we are allowing cuting edge medical technologies to reach patients faster and more efficiently than ever before. This is exactly the kind of partnership that enables the UK to stay at the forefront of global life sciences. Importantly, this is just the beginning, and I am looking forward to building on the growing US-UK collaboration as we continue to strengthen our shared commitment to safe, high- quality innovation for patients.” Working closely with trusted global
regulators is a key part of MHRA’s ambition to ensure the UK remains world leading in life sciences research, development, and launching innovative new products. This will give companies clearer, more predictable processes and help patients access safe, new technologies sooner, complementing the economic and health benefits delivered through the wider US-UK partnership.
Nanopore partnership expanded
Molecular diagnostics firm Cepheid and Oxford Nanopore Technologies, the company delivering a new generation of nanopore-based molecular sensing technology for real-time genomic analysis, have announced an expansion of their partnership to develop a workflow for rapid bacterial and fungal pathogen identification. Following a successful phase one
collaboration announced at ESCMID Global 2025, the companies are advancing to the next phase of development, building on a promising beta solution already in use by researchers. In this next phase, the updated
workflow will enable pathogen identification, antimicrobial resistance profiling, and genomic antibiotic susceptibility testing predictions for bloodstream infection and sepsis research. These analyses will be performed using both culture isolates and positive blood cultures. This phase will include additional user-friendly product design elements and expanded access through a co-commercialised research use only (RUO) launch.
14
WWW.PATHOLOGYINPRACTICE.COM May 2026
“Phase two reflects our shared
commitment to making advanced infectious disease research more practical and widely achievable,” said Vitor Rocha, President of Cepheid. “By leveraging the scale and simplicity of Cepheid’s GeneXpert platform together with Oxford Nanopore’s sequencing technology, we are increasing access to critical infectious disease information.” The initial workflow, designed to profile
bacterial and fungal pathogens from culture isolates for sepsis and bloodstream infection research, has shown promise. Multiple infectious disease researchers already have early beta access, and by Q3-2026, the workflow will be available through an early access programme to several leading physician-scientists.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52
